Back to search

University of Crete (UOC)

Ο ρόλος των μικρών πλούσιων σε λευκίνη πρωτεογλυκανών (SLRPs) στη συμπεριφορά των καρκινικών κυττάρων ανθρώπινου οστεοσαρκώματος

Abstract

dc:description

Osteosarcomas comprise approximately 1% of total malignant tumors diagnosed every year and they have a mesenchymal origin. Osteosarcoma is the second most common primary bone tumor, after myeloma and 20% of all sarcomas of the bone are osteosarcomas. Its incidence is higher during the second decade and lower in the sixth decade of the human life. An important characteristic of osteosarcoma is its heterogeneity and ability to produce abundant non-mineralized ECM–osteoid, mainly consisting of collagen type I, glycoproteins, and proteoglycans (PGs)/GAGs (Benayahu et al., 2001; Nikitovic et al., 2013).The small leucine-rich proteoglycans (SLRPs) were originally defined as proteoglycans with a relatively small protein core (36–42 kDa) harboring tandem leucine-rich repeats and undergoing post-translational modifications, including substitution with glycosaminoglycan side chains of various types (Iozzo and Murdoch 1996; Iozzo 1997). Their ubiquitous tissue distribution and expression at strategic sites in embryogenesis and tissue repair, coupled with their protein conservation, suggests that SLRP functions are of no small consequence. Originally, the SLRPs were grouped into three distinct classes based on nucleotide and protein sequence conservation, the organization of disulfide bonds at their N and C termini, and their genomic organization (Iozzo 1997; Danielson et al., 1993). More recently, the SLRP gene family has expanded to encompass 18 genes classified into five distinct subfamilies (Schaefer and Iozzo 2008; Iozzo et al., 2011), additionally based on N-terminal Cys-rich clusters of the protein core and ear repeats (C-terminal repeats specific to SLRPs) (McEwan et al., 2006), chromosomal organization (Schaefer and Iozzo 2008; Iozzo et al., 2011), and, importantly, functional commonality in view of the fact that some SLRPs are not classical proteoglycans (Schaefer and Iozzo 2008). Thus, the canonical class I members decorin and biglycan contain chondroitin or dermatan sulfate side chains, whereas the more recently described asporin does not (Henry et al., 2001; Kisawa et al., 2005). On the other hand, all class II members bear keratan sulfate chains or polylactosamine in their leucine-rich repeats, whereas class III members carry keratan sulfate (osteoglycin), chondroitin/dermatan sulfate (epiphycan), or no glycosaminoglycan (opticin) chains (Schaefer and Iozzo 2008, Sanders et al., 2003). However, most non-canonical class IV and V members (Neame et al., 1994; Pusch et al., 2000; Ohta et al., 2006) unexpectedly lack any glycosaminoglycan chain, with the exception of chondroadherin, which is substituted with keratan sulfate (Neame et al., 1994). Therefore, the unique characteristics of their protein cores and the presence of glycosaminoglycans, together with specific post-translational modifications, notably changes in the degree of glycosaminoglycan epimerization or sulfation, characterize this class of proteoglycans with high structural complexity.The present PhD thesis investigated the role of two important SLRPs, lumican and biglycan, in the regulation of osteosarcoma cell function. Our research group has shown that human osteosarcoma cell lines express and secrete lumican partly substituted with keratan sulfate glycosaminoglycans Nikitovic et al., 2008. Lumican appears to have a role in osteosarcoma pathogenesis, as the growth of Saos 2 osteosarcoma cells was inhibited by lumican, whereas their migration and chemotactic response to fibronectin were found to be promoted (Nikitovic et al., 2008). These key tumor cell functions appear to be modulated through, crucial for bone tumor cells, Smad signaling pathway (Nikitovic et al., 2008). In this study, we examine the effect of lumican on osteosarcoma cell adhesion and investigate the hypothesis that lumican through the modulation of the pericellular availability of the transforming growth factor-beta (TGF-β) isoform/s regulates its downstream intracellular signaling and thus affects cell functions. Human osteosarcoma cell lines were recently shown to express and secrete the small leucine rich proteoglycan (SLRP) lumican, with the ability to regulate the growth and motility of these cells. In this study, lumican-deficient Saos 2 cells were demonstrated to have increased adhesive capability onto fibronectin (FN) (p≤0.01). Upon neutralization of endogenous transforming growth factor β2 (TGF-β2) activity, no difference in the ability of lumican siRNA-transfected and scramble siRNA-transfected Saos 2 cells to adhere onto FN was detected (p = NS). Exogenous TGF-β2 was shown to stimulate Saos 2 cell adhesion to FN (p≤0.01). These results therefore, suggest that the inverse correlation existing between lumican expression and Saos 2 cell adhesion is dependent on active TGF-β signaling. Furthermore, the significant increase in Smad 2 activation present in lumican-deficient cells (p≤0.01) was annulled in the presence of the anti-TGF-β2 peptide, demonstrating that lumican is an upstream regulator of the TGF-β2/Smad 2 signaling cascade. Crucial to FN-dependent adhesion, β1 integrin expression and pFAK activation were likewise identified as downstream TGF-β2 effectors regulated by lumican expression. In conclusion, this study demonstrates a novel out-in signaling circuit in human osteosarcoma cells: secreted to extracellular matrix lumican is an endogenous inhibitor of TGF-β2 activity, resulting in downstream effector modulation including pSmad 2, integrin β1 and pFAK to regulate osteosarcoma adhesion.Furthermore, this study investigated osteosarcoma cell function modulation of the equally important SLRP, biglycan.Biglycan, a small leucine rich proteoglycan (SLRP), is an important participant in bone homeostasis and development as well as in bone pathology. In the present study biglycan was identified as a positive regulator of MG63 osteosarcoma cell growth (p ≤ 0.001). IGF-I was shown to increase biglycan expression (p ≤ 0.01), whereas biglycan-deficiency attenuated significantly both basal and IGF-I induced cell proliferation of MG63 cells (p ≤ 0.001; p ≤ 0.01, respectively). These effects were executed through the IGF-IR receptor whose activation was strongly attenuated (p ≤ 0.01) in biglycan-deficient MG63 cells. Biglycan, previously shown to regulate Wnt/b-catenin pathway, was demonstrated to induce a significant increase in b-catenin protein expression evident at cytoplasmic (p ≤ 0.01), membrane (p ≤ 0.01), and nucleus fractions in MG63 cells (p ≤ 0.05). As demonstrated by immunofluorescence, increase in b-catenin expression is attributed to co-localization of biglycan with the Wnt co-receptor low-density lipoprotein receptor-related protein 6 (LRP6) resulting in attenuated b-catenin degradation. Furthermore, applying anti-b-catenin and anti-pIGF-IR antibodies to MG-63 cells demonstrated a cytoplasmic and to the membrane interaction between these molecules that increased upon exogenous biglycan treatment. In parallel, the downregulation of biglycan significantly inhibited both basal and IGF-I-dependent ERK1/2 activation, (p ≤ 0.001). In summary, we report a novel mechanism where biglycan through a LRP6/b-catenin/IGF-IR signaling axis enhances osteosarcoma cell growth (Aggelidakis et al., 2018).In summary, the results of this PhD thesis described two novel mechanisms with which two important cancer cell functions were modulated, adhesion and proliferation by lumican and biglycan respectively. These SLRPs are suggested to be used as target molecules for the regulation of osteosarcoma progression and maybe part of therapy treatments for tumors of mesenchymal origin.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2019

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Angelidakis, Ioannis
  • Αγγελιδάκης, Ιωάννης

Subjects

dc:subject × 17

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/45980

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Angelidakis, Ioannis; Αγγελιδάκης, Ιωάννης. Ο ρόλος των μικρών πλούσιων σε λευκίνη πρωτεογλυκανών (SLRPs) στη συμπεριφορά των καρκινικών κυττάρων ανθρώπινου οστεοσαρκώματος. University of Crete (UOC), 2019. http://hdl.handle.net/10442/hedi/45980